Secondary Logo

Journal Logo

Most Popular Articles

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Diem, Stefan; Fässler, Mirjam; Bomze, David; More

Journal of Immunotherapy. 42(3):89-93, April 2019.

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy

Liu, Yanfen; Chen, Xinfeng; Wang, Dao; More

Journal of Immunotherapy. 41(9):406-410, November/December 2018.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; More

Journal of Immunotherapy. 40(9):334-340, November/December 2017.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

Nowicki, Theodore S.; Escuin-Ordinas, Helena; Avramis, Earl; More

Journal of Immunotherapy. 41(5):248-259, June 2018.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient

Pollack, Seth M.; Lu, Hailing; Gnjatic, Sacha; More

Journal of Immunotherapy. 40(8):302-306, October 2017.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Lindenberg, Melanie A.; Retèl, Valesca P.; van den Berg, Joost H.; More

Journal of Immunotherapy. 41(9):413-425, November/December 2018.

Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

Keilholz, Ulrich; Weber, Jeffrey; Finke, James H.; More

Journal of Immunotherapy. 25(2):97-138, March-April 2002.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma The Mecolit Survey

Lesage, Candice; Longvert, Christine; Prey, Sorilla; More

Journal of Immunotherapy. 42(5):175-179, June 2019.

Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy

Odegard, Jared M.; Kelley-Clarke, Brenna; Tareen, Semih U.; More

Journal of Immunotherapy. 38(2):41-53, February/March 2015.

Adoptive Cellular Therapy With Tumor Vaccine Draining Lymph Node Lymphocytes After Vaccination With HLA-B7/β2-Microglobulin Gene-Modified Autologous Tumor Cells

Meijer, Sybren L.; Dols, Annemieke; Urba, Walter J.; More

Journal of Immunotherapy. 25(4):359-372, July-August 2002.

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells

Merz, Christian; Sykora, Jaromir; Marschall, Viola; More

Journal of Immunotherapy. 41(9):385-398, November/December 2018.

Homing of Tumor-Specific T Cells in the B16-OVA/OT-I Model System - towards T Cells as Carriers of Cytotoxic Substances in Therapy of Cancer

Petersen, Mikkel S; Fleischer, Charlotte C; Hansen, Søren B; More

Journal of Immunotherapy. 27(6):S36, November-December 2004.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial

Cohn, Allen; Morse, Michael A.; O’Neil, Bert; More

Journal of Immunotherapy. 41(3):141-150, April 2018.

Role of Interferon (IFN)α in “Cocktails” for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions

Hirn Lopez, Annika; Deen, Diana; Fischer, Zuzanna; More

Journal of Immunotherapy. 42(5):143-161, June 2019.

The Novel Chimeric Anti-NCAM (Neural Cell Adhesion Molecule) Antibody ch.MK1 Displays Antitumor Activity in SCID Mice but Does not Activate Complement-Dependent Cytolysis (CDC)

Klehr, Martin; Koehl, Ulrike; Mühlenhoff, Martina; More

Journal of Immunotherapy. 32(5):442-451, June 2009.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; More

Journal of Immunotherapy. 37(2):105-114, February/March 2014.

Freeze-Thawing Procedures Have No Influence on the Phenotypic and Functional Development of Dendritic Cells Generated from Peripheral Blood CD14+ Monocytes

Hori, Shin-ichi; Heike, Yuji; Takei, Masao; More

Journal of Immunotherapy. 27(1):27-35, January-February 2004.

The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro

Dupuis, Maria L.; Fiori, Valentina; Soriani, Alessandra; More

Journal of Immunotherapy. 38(9):357-370, November/December 2015.

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

Duell, Johannes; Lukic, Dragana S.; Karg, Margarete; More

Journal of Immunotherapy. 42(5):180-188, June 2019.

Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer

Scholl, Susy M.; Balloul, Jean-Marc; Le Goc, Gwenaelle; More

Journal of Immunotherapy. 23(5):570-580, September-October 2000.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

Goff, Stephanie L.; Morgan, Richard A.; Yang, James C.; More

Journal of Immunotherapy. 42(4):126-135, May 2019.

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

Chandra, Janin; Dutton, Julie L.; Li, Bo; More

Journal of Immunotherapy. 40(2):62-70, February/March 2017.

Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases

Mehta, Gautam U.; Malekzadeh, Parisa; Shelton, Thomas; More

Journal of Immunotherapy. 41(5):241-247, June 2018.

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

Monk, Paul; Lam, Elaine; Mortazavi, Amir; More

Journal of Immunotherapy. 37(3):180-186, April 2014.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

Boudewijns, Steve; Westdorp, Harm; Koornstra, Rutger H.T.; More

Journal of Immunotherapy. 39(6):241-248, July/August 2016.

Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies

Kerkar, Sid P.; Sanchez-Perez, Luis; Yang, Shicheng; More

Journal of Immunotherapy. 34(4):343-352, May 2011.

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program

Bisschop, Cornelis; Wind, Thijs T.; Blank, Christian U.; More

Journal of Immunotherapy. 42(6):208-214, July/August 2019.

Dendritic Cells Loaded With MART-1 Peptide or Infected With Adenoviral Construct Are Functionally Equivalent in the Induction of Tumor-Specific Cytotoxic T Lymphocyte Responses in Patients With Melanoma

Philip, Ramila; Alters, Susan E.; Brunette, Elisa; More

Journal of Immunotherapy. 23(1):168-176, January 2000.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Fischer, Jeannette; Paret, Claudia; El Malki, Khalifa; More

Journal of Immunotherapy. 40(5):187-195, June 2017.

Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients

Speiser, Daniel E.; Schwarz, Katrin; Baumgaertner, Petra; More

Journal of Immunotherapy. 33(8):848-858, October 2010.

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

Lam, Elaine T.; Wong, Michael K. K.; Agarwal, Neeraj; More

Journal of Immunotherapy. 37(7):360-365, September 2014.

A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer

Suzuki, Nobuaki; Hazama, Shoichi; Ueno, Tomio; More

Journal of Immunotherapy. 37(1):36-42, January 2014.

Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

Christensen, Olaf; Lupu, Alaviana; Schmidt, Stefanie; More

Journal of Immunotherapy. 32(6):613-621, July-August 2009.